lubiprostone has been researched along with Colonic Inertia in 131 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 35 (26.72) | 29.6817 |
| 2010's | 68 (51.91) | 24.3611 |
| 2020's | 28 (21.37) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, MH; Dai, N; Fang, XC; He, SX; Hou, XH; Li, YQ; Liu, L; Liu, S; Liu, XW; Liu, YL; Shen, XZ; Sun, MJ; Tian, A; Tian, ZB; Wang, XY; Wen, ZL; Wu, YD; Xiao, YL; Xu, H; Zeng, WZ | 1 |
| Brenner, DM; Liu, JJ | 2 |
| Brenner, DM; Chang, CH; Harris, LA; Kassebaum-Ladewski, A; Poppers, DM; Sayuk, GS; Waldman, SA | 1 |
| Chang, L; Heidelbaugh, JJ; Lembo, A; Smalley, W; Sultan, S; Verne, GN | 1 |
| Kanzo, T; Kimura, T; Kiuchi, M; Nagazumi, A; Ohbayashi, H; Sato, Y | 1 |
| Almario, CV; Bharucha, AE; Chang, L; Chey, WD; Diem, S; Greer, KB; Hanson, B; Harris, LA; Imdad, A; Ko, C; Lembo, AJ; Murad, MH; Patel, A; Shah, ED; Sultan, S | 2 |
| Mairiang, P; Manasirisuk, W; Sawadpanich, K; Suttichaimongkol, T; Tangvoraphonkchai, K | 1 |
| Ahmed, ST; Bashashati, M; Fichna, J; Majewski, M; Milad, M; Sarosiek, J; Tarasiuk, A; Wallner, G | 1 |
| Ballou, S; Camilleri, M; Lembo, A; Rangan, V; Shin, A | 1 |
| Miner, PB | 1 |
| Chey, WD; Jou, J; Shah, ED; Stidham, RW; Suresh, S | 1 |
| Amano, T; Miura, S; Takenaka, T; Zeniya, M | 1 |
| Eguchi, T; Hashimura, H; Ikeoka, S; Matsuda, T; Matsumoto, M; Miura, T; Momose, K; Morisawa, T; Okada, A; Okamoto, N; Otsuka, T; Takagi, M; Yoshizaki, T | 1 |
| Habibi, S; Lichtlen, P; Rao, SSC | 1 |
| Higurashi, T; Honda, Y; Imajo, K; Iwaki, M; Kato, S; Kato, T; Kessoku, T; Kirikoshi, H; Kobayashi, N; Kobayashi, T; Kubota, K; Nakajima, A; Ogawa, Y; Ozaki, A; Saito, S; Taguri, M; Tomeno, W; Usuda, H; Wada, K; Yamanaka, T; Yoneda, M | 1 |
| Medina-Centeno, R | 1 |
| Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K | 1 |
| Esumi, S; Kajizono, M; Kitamura, Y; Sada, H; Sendo, T; Ushio, S | 1 |
| Amioka, S; Eguchi, T; Fujinami, M; Ikeoka, S; Inoue, K; Katayama, N; Matsuda, T; Matsumoto, M; Momose, K; Morisawa, T; Noda, M; Nonaka, T; Okada, A; Sako, T; Takagi, M; Yamaguchi, T; Yoshizaki, T | 1 |
| Asano, T; Kimura, T; Kiuchi, M; Nagazumi, A; Ohbayashi, H; Sato, Y | 1 |
| Adams, A; Barish, C; Chen, A; Dennis, P; Krause, R; Lichtlen, P; Losch-Beridon, T; Mareya, S; Schneider, J | 1 |
| Benninga, MA; Clifford, RA; Di Lorenzo, C; Hussain, SZ; Hyman, P; Lichtlen, P; Losch-Beridon, T; Mareya, S; Nurko, S; O'Gorman, M; Sood, MR | 1 |
| Black, CJ; Ford, AC; Houghton, LA; Lacy, BE; Lugo-Fagundo, NS; Nelson, AD | 1 |
| Kawakami, E; Kimura, M; Miyazaki, C; Nagamura, M; Ooba, N; Sato, T; Shimada, M; Takahashi, M; Takahashi, Y; Tokuyoshi, J; Ushida, M | 1 |
| Kawamoto, R; Kikuchi, A; Kumagi, T; Ninomiya, D | 1 |
| Clifford, R; Hussain, SZ; Labrum, B; Mareya, S; Stripling, S | 1 |
| Fukushima, S; Handa, O; Handa, Y; Matsumoto, H; Murao, T; Osawa, M; Shiotani, A; Umegaki, E; Yo, S | 1 |
| Morrow, T | 1 |
| Kim, SJ; Park, KS | 1 |
| Chey, WD; Cryer, B; Drossman, DA; Habibi, S; Wang, M; Webster, L | 1 |
| Gotfried, J; Schey, R | 1 |
| Cryer, B; Drossman, DA; Losch-Beridon, T; Mareya, SM; Mazen Jamal, M; Spierings, ELH; Wang, M | 1 |
| Murphy, JA; Sheridan, EA | 1 |
| Higurashi, T; Honda, Y; Imajo, K; Kato, S; Kato, T; Kessoku, T; Kirikoshi, H; Kobayashi, T; Kubota, K; Nakajima, A; Ogawa, Y; Saito, S; Taguri, M; Tomeno, W; Usuda, H; Wada, K; Yamanaka, T; Yoneda, M | 1 |
| Brewer, RP; Lichtlen, P; Losch-Beridon, T; Mareya, S; Wang, M; Webster, LR | 1 |
| Black, CJ; Burr, NE; Ford, AC; Houghton, LA; Moayyedi, P; Quigley, EMM | 1 |
| Hirose, T; Kawachi, Y; Kuroda, A; Mitsuoka, M; Mori, K; Shinoda, Y; Sugiyama, T; Takeda, A; Tanaka, K; Yoshida, A; Yoshimura, T | 1 |
| Nakamura, T; Node, K; Sato, E; Takeshita, M; Tanaka, A | 1 |
| Müller-Lissner, S | 1 |
| Cremonini, F; Gras-Miralles, B | 1 |
| Brenner, DM; Ford, AC; Schoenfeld, PS | 1 |
| Di Lorenzo, C; Hyman, PE; Prestridge, LL; Ueno, R; Youssef, NN | 1 |
| Rao, S; Weber, HC | 1 |
| Faure, C | 1 |
| Ali, H; Thayalasekeran, S; Tsai, HH | 1 |
| De Ponti, F; Raschi, E | 1 |
| Cryer, B; Katz, S; Popescu, A; Ueno, R; Vallejo, R | 1 |
| Cummings, MA; Meyer, JM | 1 |
| Fukudo, S; Hongo, M; Kaneko, H; Takano, M; Ueno, R | 2 |
| Ford, AC; Littlehales, EG | 1 |
| Blum, SI; Carson, RT; Friedman, M; Huang, H; Menzin, J; Munsell, M; Sarocco, P; Taylor, DC | 1 |
| Bateman, J; Grover, B; Jesselson, M; Lee, J; Marciniak, CM; Tierny, J; Toledo, S | 1 |
| Merello, M; Perez-Lloret, S; Rossi, M | 1 |
| Caporaso, JG; Crowell, MD; DiBaise, JK; Ilhan, ZE; Kang, DW; Krajmalnik-Brown, R; Rideout, JR; Rittmann, BE | 1 |
| Adams, AB; Jamal, MM; Jansen, JP; Webster, LR | 1 |
| Iwata, Y; Kunishi, Y; Yoshie, K | 1 |
| Luthin, DR; Thomas, RH | 1 |
| Ando, Y; Gyawali, B; Hayashi, N; Honda, K; Shimokata, T; Tsukuura, H | 1 |
| Benninga, MA; Di Lorenzo, C; Dinning, PG; Koppen, IJ; Levitt, MA; Saps, M; Yacob, D | 1 |
| Gupta, A | 1 |
| Weber, HC | 1 |
| Gao, X; Macahilig, C; Mehta, S; Mody, R; Patel, H; Solem, CT | 1 |
| Holder, RM; Rhee, D | 1 |
| Brewer, RP; Losch-Beridon, T; Mareya, SM; Rauck, RL; Spierings, EL | 1 |
| Fu, T; Gao, Y; Li, CX; Li, F; Liu, BH; Tong, WD; Wang, XF; Wu, JS; Zhang, AP | 1 |
| Alvarez, A; Bashashati, M; Gomez, Y; Hall, M; McCallum, RW; Sarosiek, I; Sarosiek, J; Shankar, N | 1 |
| Chang, L; Chey, WD; Drossman, D; Lichtlen, P; Losch-Beridon, T; Mareya, S; Wang, M | 1 |
| Flores, CA | 1 |
| Carter, LA; Christie, J; Dietz-Lindo, KA; Hanfelt, J; Harrison, MS; Shahnavaz, N; Shroff, S; Srinivasan, S | 1 |
| Lang, L | 1 |
| Cash, BD; Chang, L; Sabesin, SM; Vitat, P | 1 |
| Ambizas, EM; Ginzburg, R | 2 |
| Lacy, BE; Levy, LC | 2 |
| Fried, M; Pohl, D; Tutuian, R | 1 |
| Kapoor, S | 3 |
| Chey, WD; Drossman, DA; Fass, R; Johanson, JF; Panas, R; Scott, C; Ueno, R | 1 |
| Chey, WD; Saad, R | 1 |
| Rao, SS; Tuteja, AK | 1 |
| Owen, RT | 1 |
| Chey, WD; Lacy, BE | 1 |
| Gale, JD | 1 |
| Ueno, R | 1 |
| Jentsch, TJ | 1 |
| Carter, NJ; Scott, LJ | 1 |
| Wood, JD | 1 |
| Barish, CF; Drossman, D; Johanson, JF; Ueno, R | 1 |
| Anderson, PJ; O'Brien, CE; Stowe, CD | 2 |
| Bohn, LM; Fei, G; Liu, S; Qu, MH; Raehal, K; Schmid, CL; Sun, X; Wang, GD; Wang, XY; Wood, JD; Xia, Y | 1 |
| Adam, B; Gerken, G; Liebregts, T | 1 |
| Rao, SS; Singh, S | 1 |
| Ford, AC; Suares, NC | 1 |
| Fukudo, S; Hongo, M; Kaneko, H; Ueno, R | 1 |
| Camilleri, M; Wong, BS | 1 |
| Rao, SS; Schey, R | 1 |
| Johanson, JF; Lembo, AJ; Miner, PB; Parkman, HP; Rao, SS; Ueno, R | 1 |
| Liu, LW | 1 |
| Camilleri, M | 1 |
| Chey, WD; Drossman, DA; Johanson, JF; Panas, RM; Scott, C; Ueno, R | 1 |
| Chong, K; Kim, S; Lembo, A; Pimentel, M; Shah, E | 1 |
| Davidson, A; Hunter, C; Jahan, I; Kenney, C; McCombs, A; Miller, A; Ondo, WG; Sullivan, K; Zesiewicz, TA | 1 |
| Chamberlain, SM; Rao, SS | 1 |
| Dolgin, E | 1 |
| Ford, AC; Talley, NJ | 1 |
| Deepak, P; Samo, S; Sherid, M; Sifuentes, H; Sridhar, S | 1 |
| Winpenny, JP | 1 |
| Camilleri, M; Schiller, LR | 1 |
| McKeage, K; Plosker, GL; Siddiqui, MA | 1 |
| Bleser, SD | 1 |
| Crowell, MD; DiBaise, JK; Harris, LA; Olden, KW | 1 |
| Chagan, L; Rivkin, A | 1 |
| Johanson, JF; Ueno, R | 1 |
| Benninga, MA; Di Lorenzo, C; Liem, O; Mousa, HM | 1 |
| Thomas, J | 1 |
| Geenen, J; Johanson, JF; Morton, D; Ueno, R | 1 |
| Cash, BD; Chang, E; Talley, NJ; Wald, A | 1 |
| Baker, DE | 1 |
| Drossman, DA; Johanson, JF; Panas, R; Ueno, R; Wahle, A | 1 |
52 review(s) available for lubiprostone and Colonic Inertia
| Article | Year |
|---|---|
Review article: current and future treatment approaches for IBS with constipation.
Topics: Constipation; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone; Quality of Life; Treatment Outcome | 2021 |
Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
Topics: Chronic Disease; Constipation; Gastrointestinal Agents; Guanylyl Cyclase C Agonists; Humans; Irritable Bowel Syndrome; Isoquinolines; Lubiprostone; Natriuretic Peptides; Peptides; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Medications for constipation in 2020.
Topics: Adult; Child; Chloride Channel Agonists; Constipation; Humans; Lubiprostone; Quality of Life | 2020 |
Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation.
Topics: Constipation; Flatulence; Humans; Irritable Bowel Syndrome; Lubiprostone; Pharmaceutical Preparations; Treatment Outcome | 2021 |
Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation.
Topics: Constipation; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone; Quality of Life; Treatment Outcome | 2021 |
[Pharmacotherapy in Patients with Chronic Constipation].
Topics: Cathartics; Chloride Channel Agonists; Constipation; Dietary Fiber; Guanylyl Cyclase C Agonists; Humans; Laxatives; Lubiprostone; Peptides; Polyethylene Glycols; Probiotics; Serotonin 5-HT4 Receptor Agonists | 2017 |
Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.
Topics: Chloride Channel Agonists; Constipation; Humans; Lubiprostone; Nausea | 2017 |
Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain.
Topics: Analgesics, Opioid; Chronic Pain; Constipation; Evidence-Based Practice; Humans; Laxatives; Lubiprostone; Morphinans; Naltrexone; Narcotic Antagonists; Piperidines; Polyethylene Glycols; Quaternary Ammonium Compounds; Randomized Controlled Trials as Topic | 2018 |
Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
Topics: Adult; Constipation; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Isoquinolines; Lubiprostone; Male; Middle Aged; Natriuretic Peptides; Network Meta-Analysis; Peptides; Randomized Controlled Trials as Topic; Secretagogues; Sulfonamides; Treatment Outcome | 2018 |
Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments.
Topics: Alprostadil; Anthraquinones; Benzofurans; Bisacodyl; Chronic Disease; Constipation; Dose-Response Relationship, Drug; Humans; Laxatives; Lubiprostone; Peptides; Polyethylene Glycols; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly.
Topics: Aged; Aged, 80 and over; Aging; Alprostadil; Analgesics, Opioid; Chronic Disease; Constipation; Female; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Parkinson Disease; Randomized Controlled Trials as Topic | 2013 |
Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis.
Topics: Alprostadil; Analgesics, Opioid; Benzofurans; Constipation; Female; Gastrointestinal Agents; Humans; Lubiprostone; Male; Naloxone; Naltrexone; Narcotic Antagonists; Peptides; Piperidines; Quaternary Ammonium Compounds; Receptors, Opioid, mu | 2013 |
New treatment targets for the management of irritable bowel syndrome.
Topics: Alprostadil; Constipation; Female; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Peptides; Quality of Life; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Treatment Outcome | 2014 |
Novel therapies for constipation.
Topics: Alprostadil; Animals; Benzofurans; Calcium Channel Agonists; Constipation; Defecation; Enzyme Activators; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Lubiprostone; Peptides; Serotonin 5-HT4 Receptor Agonists; Treatment Outcome | 2013 |
Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
Topics: Alprostadil; Animals; Chloride Channel Agonists; Chloride Channels; Clinical Trials as Topic; Constipation; Humans; Irritable Bowel Syndrome; Lubiprostone; Treatment Outcome | 2014 |
Management of constipation in Parkinson's disease.
Topics: Alprostadil; Constipation; Defecation; Gastrointestinal Transit; Humans; Laxatives; Lubiprostone; Parkinson Disease; Polyethylene Glycols; Quality of Life | 2015 |
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Topics: Chronic Disease; Clinical Trials, Phase III as Topic; Constipation; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Laxatives; Lubiprostone; Peptides | 2015 |
Opioid-induced constipation.
Topics: Chloride Channel Agonists; Chronic Pain; Constipation; Humans; Laxatives; Lubiprostone; Naloxone; Oxycodone; Peptides; Phenols; Receptors, Opioid, mu; Tapentadol | 2015 |
Childhood constipation: finally something is moving!
Topics: Anal Canal; Cathartics; Chenodeoxycholic Acid; Child; Chloride Channel Agonists; Colon; Constipation; Dietary Fiber; Dietary Supplements; Dipeptides; Electrodes, Implanted; Gastrointestinal Transit; Humans; Lubiprostone; Manometry; Medical History Taking; Peptides; Physical Examination; Receptors, Ghrelin; Rectum; Serotonin Agents; Therapeutic Irrigation; Thiazepines; Transcutaneous Electric Nerve Stimulation | 2016 |
Opioid-induced constipation in chronic noncancer pain.
Topics: Analgesics, Opioid; Chloride Channel Agonists; Chronic Pain; Constipation; Humans; Lubiprostone; Morphinans; Naltrexone; Narcotic Antagonists; Polyethylene Glycols; Quaternary Ammonium Compounds; Receptors, Opioid, mu | 2016 |
Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
Topics: Administration, Oral; Analgesics, Opioid; Chronic Pain; Constipation; Humans; Lubiprostone; Morphinans; Narcotic Antagonists; Polyethylene Glycols; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Treatment Outcome | 2016 |
Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Constipation; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Laxatives; Lubiprostone; Male; Middle Aged; Randomized Controlled Trials as Topic; Young Adult | 2016 |
Update on the management of adults with chronic idiopathic constipation.
Topics: Adult; Alprostadil; Chronic Disease; Constipation; Dietary Fiber; Female; Gastrointestinal Transit; Humans; Indoles; Laxatives; Life Style; Lubiprostone; Male; Serotonin Receptor Agonists | 2007 |
Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders.
Topics: Adult; Alprostadil; Chloride Channels; Chronic Disease; Clinical Trials as Topic; Constipation; Female; Humans; Irritable Bowel Syndrome; Lubiprostone | 2008 |
Lubiprostone: a novel treatment for chronic constipation.
Topics: Aged; Alprostadil; Chloride Channels; CLC-2 Chloride Channels; Constipation; Gastrointestinal Agents; Humans; Lubiprostone; Randomized Controlled Trials as Topic | 2008 |
Pharmacologic treatment of constipation: what is new?
Topics: Alprostadil; Animals; Chronic Disease; Constipation; Drug Therapy; Drugs, Investigational; Humans; Irritable Bowel Syndrome; Lubiprostone; Probiotics; Serotonin 5-HT4 Receptor Agonists | 2008 |
Lubiprostone--a novel treatment for irritable bowel syndrome with constipation.
Topics: Alprostadil; Clinical Trials as Topic; Constipation; Drug Interactions; Humans; Irritable Bowel Syndrome; Lubiprostone | 2008 |
Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
Topics: Alprostadil; Chloride Channels; Chronic Disease; CLC-2 Chloride Channels; Constipation; Gastrointestinal Agents; Humans; Ion Channel Gating; Irritable Bowel Syndrome; Lubiprostone; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Topics: Alprostadil; Azabicyclo Compounds; Benzofurans; Chloride Channels; Chronic Disease; Constipation; Gastrointestinal Agents; Gastrointestinal Motility; Guanylate Cyclase; Humans; Indoles; Irritable Bowel Syndrome; Laxatives; Lubiprostone; Peptides; Safety; Serotonin 5-HT4 Receptor Agonists; Serotonin Receptor Agonists; Treatment Outcome | 2009 |
Lubiprostone: in constipation-predominant irritable bowel syndrome.
Topics: Alprostadil; Clinical Trials, Phase III as Topic; Constipation; Dose-Response Relationship, Drug; Humans; Irritable Bowel Syndrome; Lubiprostone; Randomized Controlled Trials as Topic | 2009 |
Enteric nervous system: sensory physiology, diarrhea and constipation.
Topics: Alprostadil; Animals; Chloride Channels; Constipation; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Enteric Nervous System; Humans; Intestinal Mucosa; Lubiprostone; Male; Mechanoreceptors; Membrane Potentials; Mice; Receptors, Prostaglandin E; Sensitivity and Specificity | 2010 |
[New drugs for the treatment of constipation].
Topics: Alprostadil; Benzamides; Benzofurans; Bridged Bicyclo Compounds, Heterocyclic; Cathartics; Chloride Channel Agonists; Constipation; Humans; Irritable Bowel Syndrome; Lubiprostone; Peptides; Randomized Controlled Trials as Topic; Receptors, Guanylate Cyclase-Coupled; Receptors, Serotonin, 5-HT4 | 2010 |
Pharmacologic management of chronic constipation.
Topics: Alprostadil; Chronic Disease; Colchicine; Constipation; Guanylate Cyclase; Humans; Laxatives; Lubiprostone; Motilin; Narcotic Antagonists; Neurotrophin 3; Prebiotics; Probiotics; Receptors, Enterotoxin; Receptors, Guanylate Cyclase-Coupled; Receptors, Peptide; Surface-Active Agents | 2010 |
Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis.
Topics: Alprostadil; Benzofurans; Chronic Disease; Constipation; Diarrhea; Humans; Laxatives; Lubiprostone; Peptides; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Lubiprostone for the treatment of opioid-induced bowel dysfunction.
Topics: Alprostadil; Analgesics, Opioid; Chloride Channels; Clinical Trials as Topic; Constipation; Humans; Laxatives; Lubiprostone; Treatment Outcome | 2011 |
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
Topics: Alprostadil; Chloride Channels; Constipation; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone | 2011 |
Chronic constipation: current treatment options.
Topics: Alprostadil; Benzofurans; Chloride Channels; Chronic Disease; Constipation; Feedback, Physiological; Gastrointestinal Motility; Humans; Laxatives; Life Style; Lubiprostone; Peptides | 2011 |
New treatment options for chronic constipation: mechanisms, efficacy and safety.
Topics: Alprostadil; Bile Acids and Salts; Chloride Channels; Chronic Disease; Constipation; Gastrointestinal Agents; Humans; Indoles; Lubiprostone; Organic Anion Transporters, Sodium-Dependent; Peptides; Receptors, Serotonin, 5-HT4; Serotonin 5-HT4 Receptor Agonists; Serotonin Agents; Symporters | 2011 |
Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
Topics: Alprostadil; Antidepressive Agents, Tricyclic; Carbolines; Constipation; Diarrhea; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone; Randomized Controlled Trials as Topic; Rifamycins; Rifaximin; Serotonin Agents | 2012 |
Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
Topics: Adult; Alprostadil; Animals; Chloride Channel Agonists; Chloride Channels; CLC-2 Chloride Channels; Constipation; Dose-Response Relationship, Drug; Humans; Incidence; Irritable Bowel Syndrome; Laxatives; Lubiprostone; Nausea; Pharmacovigilance | 2012 |
Laxatives for chronic constipation in adults.
Topics: Adult; Alprostadil; Constipation; Female; Humans; Laxatives; Lubiprostone; Male; Meta-Analysis as Topic; Peptides; Randomized Controlled Trials as Topic | 2012 |
Lubiprostone.
Topics: Alprostadil; Constipation; Diarrhea; Fatty Acids; Headache; Humans; Lubiprostone; Nausea; Randomized Controlled Trials as Topic | 2005 |
Lubiprostone: RU 0211, SPI 0211.
Topics: Alprostadil; Bridged Bicyclo Compounds, Heterocyclic; Chloride Channels; Clinical Trials as Topic; Constipation; Digestive System Diseases; Drugs, Investigational; Fatty Acids; Humans; Ileus; Ion Channel Gating; Irritable Bowel Syndrome; Lubiprostone; Postoperative Complications | 2005 |
Chronic constipation: let symptom type and severity direct treatment.
Topics: Alprostadil; Cathartics; Chronic Disease; Constipation; Dietary Fiber; Fatty Acids; Gastroenterology; Gastrointestinal Agents; Humans; Indoles; Lubiprostone; Referral and Consultation | 2006 |
Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation.
Topics: Alprostadil; Chloride Channel Agonists; Chloride Channels; Chronic Disease; CLC-2 Chloride Channels; Constipation; Diarrhea; Fatty Acids; Humans; Lubiprostone; Models, Biological; Nausea; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Lubiprostone: chloride channel activator for chronic constipation.
Topics: Alprostadil; Animals; Chloride Channels; Chronic Disease; CLC-2 Chloride Channels; Clinical Trials as Topic; Constipation; Fatty Acids; Humans; Ion Channel Gating; Lubiprostone; Treatment Outcome | 2006 |
Lubiprostone: a chloride channel activator.
Topics: Alprostadil; Cathartics; Chloride Channels; Chlorides; Chronic Disease; Constipation; Fatty Acids; Female; Gastrointestinal Transit; Humans; Lubiprostone; Male | 2007 |
Novel and alternative therapies for childhood constipation.
Topics: Acupuncture Therapy; Alprostadil; Botulinum Toxins; Child; Complementary Therapies; Constipation; Electric Stimulation; Fatty Acids; Humans; Indoles; Lubiprostone; Massage; Piperidines; Probiotics; Serotonin Receptor Agonists | 2007 |
Lubiprostone: a chloride channel activator for treatment of chronic constipation.
Topics: Alprostadil; Chloride Channel Agonists; Chronic Disease; Constipation; Fatty Acids; Humans; Lubiprostone | 2007 |
Cancer-related constipation.
Topics: Alprostadil; Constipation; Fatty Acids; Gastrointestinal Agents; Humans; Indoles; Lubiprostone; Naltrexone; Narcotic Antagonists; Neoplasms; Piperidines; Quaternary Ammonium Compounds; Serotonin Receptor Agonists | 2007 |
Managing the chronically constipated adult: emerging approaches to diagnosis and treatment.
Topics: Aged; Alprostadil; Cathartics; Chronic Disease; Constipation; Fatty Acids; Female; Humans; Lubiprostone; Male; Middle Aged | 2007 |
Lubiprostone: a new drug for the treatment of chronic idiopathic constipation.
Topics: Alprostadil; Animals; Chloride Channels; Chronic Disease; Constipation; Drug Evaluation; Fatty Acids; Humans; Lubiprostone; Treatment Outcome | 2007 |
28 trial(s) available for lubiprostone and Colonic Inertia
| Article | Year |
|---|---|
Efficacy and safety of lubiprostone for the treatment of functional constipation in Chinese adult patients: A multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Adult; China; Chloride Channel Agonists; Constipation; Defecation; Double-Blind Method; Humans; Lubiprostone; Treatment Outcome | 2021 |
Lubiprostone plus polyethylene glycol electrolyte lavage solution (PEG-ELS) versus PEG-ELS for bowel preparation in chronic constipation: a randomized controlled trial.
Topics: Colonoscopy; Constipation; Electrolytes; Humans; Lubiprostone; Polyethylene Glycols; Thailand; Therapeutic Irrigation | 2023 |
Response to lubiprostone in chronic constipation is associated with increased mucus and mucin output: a randomized clinical trial.
Topics: Chloride Channel Agonists; Chronic Disease; Constipation; Defecation; Double-Blind Method; Gastric Mucins; Gastric Mucosa; Humans; Kansas; Lubiprostone; Mucus; Treatment Outcome | 2019 |
Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced Constipation.
Topics: Analgesics, Opioid; Constipation; Female; Homeostasis; Humans; Lubiprostone; Opioid-Induced Constipation; Secretagogues | 2021 |
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Topics: Alanine Transaminase; Constipation; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Elasticity Imaging Techniques; Female; Humans; Laxatives; Liver; Liver Function Tests; Lubiprostone; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2020 |
Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation.
Topics: Alprostadil; Constipation; Cross-Over Studies; Double-Blind Method; Humans; Lubiprostone | 2021 |
Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.
Topics: Adolescent; Adult; Child; Constipation; Defecation; Double-Blind Method; Health Personnel; Humans; Lubiprostone; Treatment Outcome | 2022 |
Safety of Lubiprostone in Pediatric Patients With Functional Constipation: A Nonrandomized, Open-Label Trial.
Topics: Adolescent; Adult; Alprostadil; Child; Constipation; Diarrhea; Humans; Lubiprostone; Treatment Outcome; Vomiting | 2021 |
Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.
Topics: Adult; Analgesics, Opioid; Chloride Channel Agonists; Chronic Pain; Constipation; Double-Blind Method; Female; Humans; Lubiprostone; Male; Methadone; Middle Aged | 2018 |
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
Topics: Alanine Transaminase; Chloride Channel Agonists; Constipation; Double-Blind Method; Elasticity Imaging Techniques; Female; Gastrointestinal Tract; Humans; Japan; Lubiprostone; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Outcome Assessment, Health Care; Permeability | 2018 |
Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.
Topics: Adult; Analgesics, Opioid; Chloride Channel Agonists; Chronic Pain; Constipation; Double-Blind Method; Female; Humans; Lubiprostone; Male; Middle Aged | 2018 |
Lubiprostone for the treatment of functional constipation in children.
Topics: Adolescent; Alprostadil; Child; Child, Preschool; Chloride Channels; Constipation; Defecation; Female; Humans; Intestinal Mucosa; Intestines; Laxatives; Lubiprostone; Male; Prospective Studies; Treatment Outcome | 2014 |
A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.
Topics: Alprostadil; Analgesics, Opioid; Chloride Channel Agonists; Chronic Pain; Constipation; Double-Blind Method; Female; Humans; Lubiprostone; Male; Middle Aged | 2014 |
Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation.
Topics: Adult; Aged; Aged, 80 and over; Constipation; Double-Blind Method; Female; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Intestines; Japan; Lubiprostone; Male; Middle Aged; Placebos; Quality of Life; Treatment Outcome; Young Adult | 2015 |
Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.
Topics: Adult; Aged; Aged, 80 and over; Alprostadil; Analgesics, Opioid; Cathartics; Chicago; Constipation; Defecation; Double-Blind Method; Female; Humans; Lubiprostone; Male; Middle Aged; Orthopedic Procedures; Pain, Postoperative; Quality of Life; Recovery of Function; Senna Extract; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2014 |
A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
Topics: Adult; Alprostadil; Analgesics, Opioid; Chloride Channel Agonists; Chronic Pain; Constipation; Defecation; Double-Blind Method; Female; Humans; Lubiprostone; Male; Middle Aged; Quality of Life; Time Factors | 2015 |
Lubiprostone for Opioid-Induced Constipation Does Not Interfere with Opioid Analgesia in Patients with Chronic Noncancer Pain.
Topics: Adult; Analgesia; Analgesics, Opioid; Chloride Channel Agonists; Chronic Pain; Constipation; Double-Blind Method; Drug Interactions; Female; Humans; Lubiprostone; Male; Middle Aged; Pain Measurement | 2017 |
Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.
Topics: Abdominal Pain; Adult; Constipation; Double-Blind Method; Female; Flatulence; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Middle Aged | 2016 |
A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients.
Topics: Aged; Chloride Channel Agonists; Colon; Constipation; Defecation; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Transit; Humans; Lubiprostone; Male; Middle Aged; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2017 |
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alprostadil; Constipation; Defecation; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Middle Aged; Patient Satisfaction; Quality of Life; Rome; Severity of Illness Index; Treatment Outcome; Young Adult | 2009 |
Efficacy and safety of lubiprostone in patients with chronic constipation.
Topics: Adult; Alprostadil; Chronic Disease; Constipation; Defecation; Double-Blind Method; Female; Follow-Up Studies; Humans; Laxatives; Lubiprostone; Male; Middle Aged; Treatment Outcome | 2010 |
Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study.
Topics: Adult; Alprostadil; Asian People; Chloride Channels; Constipation; Defecation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Middle Aged; Placebos; Treatment Outcome | 2011 |
Lubiprostone for constipation in adults with cystic fibrosis: a pilot study.
Topics: Adult; Alprostadil; Chloride Channels; CLC-2 Chloride Channels; Constipation; Cystic Fibrosis; Female; Humans; Lubiprostone; Male; Pilot Projects; Treatment Outcome; Young Adult | 2011 |
Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
Topics: Activities of Daily Living; Adult; Alprostadil; Chloride Channel Agonists; Chloride Channels; Constipation; Defecation; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Middle Aged; Quality of Life; Time Factors; Treatment Outcome | 2012 |
Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease.
Topics: Aged; Alprostadil; Constipation; Double-Blind Method; Female; Follow-Up Studies; Humans; Lubiprostone; Male; Middle Aged; Parkinson Disease; Placebos; Severity of Illness Index; Treatment Outcome; Vasodilator Agents | 2012 |
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
Topics: Adolescent; Adult; Aged; Alprostadil; Chloride Channels; Chronic Disease; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids; Female; Gastrointestinal Agents; Humans; Lubiprostone; Male; Middle Aged; Treatment Outcome | 2007 |
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
Topics: Alprostadil; Chloride Channel Agonists; Chronic Disease; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids; Female; Follow-Up Studies; Humans; Lubiprostone; Male; Middle Aged; Peristalsis; Severity of Illness Index; Treatment Outcome | 2008 |
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprostadil; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Middle Aged; Quality of Life; Treatment Outcome | 2008 |
51 other study(ies) available for lubiprostone and Colonic Inertia
| Article | Year |
|---|---|
Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.
Topics: Abdominal Pain; Constipation; Flatulence; Humans; Irritable Bowel Syndrome; Lubiprostone | 2022 |
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.
Topics: Antidepressive Agents, Tricyclic; Constipation; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Laxatives; Lubiprostone; Parasympatholytics; Polyethylene Glycols; Selective Serotonin Reuptake Inhibitors | 2022 |
Analysis of the impact on efficacy of lubiprostone dose reduction to manage adverse events in the treatment of chronic constipation in Japan.
Topics: Alprostadil; Constipation; Diarrhea; Double-Blind Method; Drug Tapering; Humans; Japan; Lubiprostone; Nausea; Treatment Outcome | 2022 |
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.
Topics: Adult; Constipation; Gastroenterology; Humans; Lactulose; Laxatives; Lubiprostone; Magnesium Oxide; Polyethylene Glycols; Quality of Life; Sennosides | 2023 |
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.
Topics: Adult; Constipation; Gastroenterology; Humans; Lactulose; Laxatives; Lubiprostone; Magnesium Oxide; Polyethylene Glycols; Quality of Life; Sennosides | 2023 |
Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey.
Topics: Attitude of Health Personnel; Constipation; Diarrhea; Diet; Dietary Fiber; Dietary Supplements; Dioctyl Sulfosuccinic Acid; Female; Gastrointestinal Agents; Health Care Surveys; Humans; Irritable Bowel Syndrome; Laxatives; Lubiprostone; Male; Middle Aged; Parasympatholytics; Patient Satisfaction; Probiotics; Rifaximin | 2020 |
Evaluating When and Why Patients Discontinue Chronic Therapy for Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation.
Topics: Chronic Disease; Constipation; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Medication Adherence; Michigan; Middle Aged; Peptides; Retrospective Studies | 2020 |
Symptomatic hyponatremia: a rare but reversible adverse reaction of lubiprostone.
Topics: Aged; Chloride Channel Agonists; Constipation; Diagnosis, Differential; Hepatitis C, Chronic; Humans; Hyponatremia; Lubiprostone; Male | 2020 |
Risk Factors for Adverse Events in Patients with Chronic Constipation Following Lubiprostone Administration.
Topics: Aged; Chronic Disease; Constipation; Feces; Female; Humans; Logistic Models; Lubiprostone; Male; Multivariate Analysis; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chloride Channel Agonists; Constipation; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Famotidine; Female; Hematologic Neoplasms; Humans; Laxatives; Lubiprostone; Lymphoma; Magnesium Oxide; Male; Middle Aged; Narcotics; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Sennosides; Vinca Alkaloids; Vincristine | 2020 |
The Efficacy and Safety of Lubiprostone for Constipation in Cancer Patients Compared with Non-cancer Patients: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Constipation; Defecation; Diarrhea; Female; Humans; Incidence; Lubiprostone; Male; Middle Aged; Nausea; Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis.
Topics: Chronic Disease; Constipation; Defecation; Dipeptides; Female; Humans; Laxatives; Lubiprostone; Male; Middle Aged; Propensity Score; Retrospective Studies; Thiazepines; Treatment Outcome | 2021 |
Open-label study to evaluate the treatment continuation rate after a dose reduction of lubiprostone due to onset of adverse events.
Topics: Adult; Aged; Chloride Channel Agonists; Chronic Disease; Constipation; Diarrhea; Drug Tapering; Female; Humans; Lubiprostone; Male; Middle Aged; Nausea; Vomiting; Withholding Treatment | 2021 |
Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Chloride Channel Agonists; Chronic Disease; Cohort Studies; Constipation; Dipeptides; Female; Gastrointestinal Agents; Humans; Japan; Lubiprostone; Male; Middle Aged; Retrospective Studies; Surveys and Questionnaires; Thiazepines | 2021 |
Clubbed Digits Presumably Caused by Lubiprostone.
Topics: Adult; Alprostadil; Constipation; Female; Humans; Liver; Lubiprostone; Neoplasms; Osteoarthropathy, Secondary Hypertrophic | 2021 |
Evaluation of efficacy and safety of lubiprostone in patients with chronic constipation.
Topics: Aged; Chronic Disease; Constipation; Female; Humans; Lubiprostone; Male; Retrospective Studies | 2021 |
$850 Per Bowel Movement?! Hard To Justify That Cost.
Topics: Chloride Channel Agonists; Chronic Disease; Clinical Trials as Topic; Constipation; Drug Costs; Drug Prescriptions; Gastrointestinal Agents; Guanylyl Cyclase C Agonists; Humans; Laxatives; Lubiprostone; Natriuretic Peptides; Nonprescription Drugs; Peptides | 2017 |
Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.
Topics: Alprostadil; Constipation; Humans; Lubiprostone; Nausea | 2017 |
Evaluation and Comparison of Daiokanzoto and Lubiprostone for Constipation: A Retrospective Cohort Study.
Topics: Aged; Constipation; Drug Costs; Female; Glycyrrhiza uralensis; Humans; Laxatives; Lubiprostone; Male; Plant Extracts; Retrospective Studies; Rhus; Treatment Outcome | 2019 |
Effect of Lubiprostone on Urinary Protein Excretion: A Report of Two IgA Nephropathy Patients with Chronic Constipation.
Topics: Adult; Chronic Disease; Constipation; Disease Progression; Fatty Acid-Binding Proteins; Female; Glomerulonephritis, IGA; Humans; Lubiprostone; Occult Blood; Proteinuria | 2019 |
Lubiprostone in pediatric functional constipation.
Topics: Alprostadil; Constipation; Defecation; Female; Humans; Intestines; Laxatives; Lubiprostone; Male | 2014 |
Lubiprostone (Amitiza) for opioid-induced constipation.
Topics: Administration, Oral; Alprostadil; Analgesics, Opioid; Constipation; Defecation; Drug Administration Schedule; Drug Costs; Gastrointestinal Agents; Gastrointestinal Transit; Humans; Lubiprostone; Treatment Outcome | 2013 |
Lubiprostone for chronic constipation in adults.
Topics: Adult; Alprostadil; Chloride Channel Agonists; Chronic Disease; Constipation; Drug Costs; Humans; Lubiprostone | 2014 |
Lubiprostone for treatment-resistant constipation associated with clozapine use.
Topics: Adult; Alprostadil; Antipsychotic Agents; Chloride Channel Agonists; Clozapine; Constipation; Humans; Lubiprostone; Male; Schizophrenia; Treatment Failure | 2014 |
Lubiprostone Is Effective in Treating Functional Bowel Disease With Constipation.
Topics: Constipation; Female; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Intestines; Lubiprostone; Male | 2015 |
Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
Topics: Adult; Chloride Channel Agonists; Constipation; Cost-Benefit Analysis; Decision Trees; Female; Gastrointestinal Agents; Health Expenditures; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Models, Economic; Peptides; Quality of Life; Treatment Outcome | 2015 |
Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone.
Topics: Adult; Aged; Biodiversity; Case-Control Studies; Chloride Channel Agonists; Chronic Disease; Constipation; Fatty Acids, Volatile; Female; Gastrointestinal Microbiome; Gene Dosage; Humans; Lubiprostone; Male; Metagenome; Middle Aged; RNA, Ribosomal, 16S; Treatment Outcome | 2015 |
Reply: To PMID 25158925.
Topics: Constipation; Female; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Intestines; Lubiprostone; Male | 2015 |
Obstructive uropathy caused by chronic constipation.
Topics: Alprostadil; Constipation; Fecal Impaction; Female; Humans; Lubiprostone; Polyethylene Glycols; Tomography, X-Ray Computed; Treatment Outcome; Urinary Tract Infections | 2015 |
Improving the recognition and diagnosis of opioid-induced constipation in clinical practice.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Chloride Channel Agonists; Constipation; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Injections, Subcutaneous; Lubiprostone; Narcotic Antagonists; Pain Management; Practice Guidelines as Topic; Primary Health Care; Quality of Life; Receptors, Opioid, mu; Treatment Outcome; United States | 2015 |
Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype.
Topics: Adult; Chloride Channel Agonists; Constipation; Female; Health Resources; Humans; Irritable Bowel Syndrome; Lubiprostone; Middle Aged; Patient Satisfaction; Quality of Life; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2016 |
Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation.
Topics: Adult; Blind Loop Syndrome; Breath Tests; Chronic Disease; Constipation; Female; Gastrointestinal Agents; Gastrointestinal Transit; Humans; Intestine, Small; Lactulose; Lubiprostone; Middle Aged; Treatment Outcome; Young Adult | 2016 |
ClC-2 and intestinal chloride secretion.
Topics: Animals; Chloride Channel Agonists; Chloride Channels; Chlorides; CLC-2 Chloride Channels; Constipation; Gene Expression Regulation; Lubiprostone | 2016 |
The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation.
Topics: Alprostadil; Constipation; Drug Approval; Humans; Irritable Bowel Syndrome; Lubiprostone; United States; United States Food and Drug Administration | 2008 |
Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
Topics: Alprostadil; Constipation; Drug Costs; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone; Treatment Outcome | 2008 |
Management of constipation in the elderly: emerging therapeutic strategies.
Topics: Age Factors; Aged; Aged, 80 and over; Alprostadil; Benzofurans; Constipation; Humans; Lubiprostone; Neostigmine | 2008 |
Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.
Topics: Alprostadil; Chloride Channel Agonists; Chronic Disease; Constipation; Dose-Response Relationship, Drug; Humans; Irritable Bowel Syndrome; Lubiprostone | 2008 |
Lubiprostone for constipation and irritable bowel syndrome with constipation.
Topics: Alprostadil; Chloride Channel Agonists; Constipation; Dose-Response Relationship, Drug; Female; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; United States; United States Food and Drug Administration | 2008 |
Lubiprostone: clinical applications beyond constipation.
Topics: Alprostadil; Animals; Chloride Channels; Constipation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Laxatives; Lubiprostone; Muscle Contraction | 2009 |
To the editor. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology.
Topics: Alprostadil; Cell Line; Chloride Channels; Constipation; Diarrhea; Humans; Lubiprostone | 2009 |
To the editor. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology.
Topics: Alprostadil; Chloride Channels; Clinical Trials as Topic; Constipation; Diarrhea; Humans; Lubiprostone | 2009 |
Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series.
Topics: Adult; Alprostadil; Chloride Channels; Constipation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Intestinal Obstruction; Lubiprostone; Male; Secondary Prevention; Treatment Outcome; Young Adult | 2010 |
Emerging new therapeutic options for the management of opioid induced constipation.
Topics: Alprostadil; Analgesics, Opioid; Constipation; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Laxatives; Lubiprostone; Naloxone; Naltrexone; Narcotic Antagonists; Oxycodone; Quaternary Ammonium Compounds | 2010 |
Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.
Topics: Alprostadil; Animals; Chloride Channels; Chlorine; CLC-2 Chloride Channels; Constipation; Dose-Response Relationship, Drug; Feces; Guinea Pigs; In Vitro Techniques; Intestinal Mucosa; Intestines; Ion Channel Gating; Lubiprostone; Male; Mice; Mice, Inbred C57BL; Morphine; Neurons; Prostaglandins | 2010 |
Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.
Topics: Adult; Alprostadil; Cathartics; Chloride Channel Agonists; Chronic Disease; Constipation; Drug Administration Schedule; Female; History, 18th Century; Humans; Lubiprostone; Male; Middle Aged | 2011 |
Drug pipeline is flush with new options for chronic constipation.
Topics: Alprostadil; Benzofurans; Biomedical Research; Chloride Channels; Constipation; Drug Approval; Humans; Lubiprostone; Peptides | 2012 |
Lubiprostone induced ischemic colitis.
Topics: Alprostadil; Chloride Channel Agonists; Colitis, Ischemic; Constipation; Female; Hemorrhage; Humans; Lubiprostone; Middle Aged; Withholding Treatment | 2013 |
Lubiprostone: viewpoints.
Topics: Alprostadil; Cathartics; Chloride Channel Agonists; Chloride Channels; CLC-2 Chloride Channels; Constipation; Fatty Acids; Female; Humans; Intestinal Mucosa; Lubiprostone; Male | 2006 |
Lubiprostone.
Topics: Adult; Alprostadil; Area Under Curve; Cathartics; Chloride Channel Agonists; Chloride Channels; CLC-2 Chloride Channels; Constipation; Fatty Acids; Female; Humans; Lubiprostone; Male; Molecular Structure; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Lubiprostone (amitiza) for chronic constipation.
Topics: Alprostadil; Chloride Channels; Chronic Disease; Clinical Trials as Topic; Constipation; Fatty Acids; Female; Gastrointestinal Agents; Humans; Lubiprostone; Pregnancy | 2006 |
Fresh perspectives in chronic constipation and other functional bowel disorders.
Topics: Adult; Alprostadil; Cathartics; Chloride Channels; Chronic Disease; Clinical Protocols; Constipation; Defecation; Fatty Acids; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Manometry; Patient Satisfaction; Treatment Outcome | 2007 |